Clinical trial · Interventional
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT01312311CI-TRIAL-00004552unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Cancer | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel, Cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- weekly docetaxel and cisplatin
- description
- Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
- interventionNames
- Drug: Docetaxel, Cisplatin
Primary outcomes (1)
- measure
- objective response rate
- timeFrame
- 6 months after the enrollment of the last patients
Secondary outcomes (1)
- measure
- number of patients with adverse events
- timeFrame
- simultaneously when the analysis of primary endpoint
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed nasopharyngeal cancer * chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment) * ECOG 0-1 * at least one measurable lesion Exclusion Criteria: * other cancer * pregnat * docetaxel hypersentitivity history * severe heart or pulmonary disease
References
Publications (0)
Data not yet available
No reference posted for this study.